ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021Business Wire • 02/19/21
New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver FunctionBusiness Wire • 02/04/21
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)Business Wire • 11/17/20
ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail PartnershipBusiness Wire • 11/09/20
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020Business Wire • 10/28/20
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, MiceBusiness Wire • 10/19/20
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell FunctionBusiness Wire • 10/08/20
ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%Business Wire • 10/06/20
New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in MiceBusiness Wire • 09/09/20
New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure PatientsBusiness Wire • 08/18/20
ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020Business Wire • 07/28/20